AACR 2023 | Management of multiple myeloma during CAR-T therapy manufacturing
For patients with relapsed/refractory multiple myeloma, CAR-T cell therapy is a promising treatment strategy. However, relatively long manufacturing times the CAR-T cells is a limiting step for many patients, who may urgently need treatment. Attaya Suvannasankha, MD, Indiana University School of Medicine, Indianapolis, IN, comments on controlling the disease during CAR-T cell production. Using antibody-drug conjugates such as belantamab mafodotin have shown to be possible in preliminary studies. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
